Apomorphine Reduces A53T α-Synuclein-Induced Microglial Reactivity Through Activation of NRF2 Signalling Pathway

The chiral molecule, apomorphine, is currently used for the treatment of Parkinson’s disease (PD). As a potent dopamine receptor agonist, this lipophilic compound is especially effective for treating motor fluctuations in advanced PD patients. In addition to its receptor-mediated actions, apomorphin...

Descripción completa

Detalles Bibliográficos
Autores principales: Heurtaux, Tony, Kirchmeyer, Melanie, Koncina, Eric, Felten, Paul, Richart, Lorraine, Uriarte Huarte, Oihane, Schohn, Herve, Mittelbronn, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560932/
https://www.ncbi.nlm.nih.gov/pubmed/34415465
http://dx.doi.org/10.1007/s10571-021-01131-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560932/
https://www.ncbi.nlm.nih.gov/pubmed/34415465
http://dx.doi.org/10.1007/s10571-021-01131-1

Ejemplares similares